Savara prices $130M public offering of common stock and pre-funded warrants at $4.20/share

Savara Inc

23.8M shares at $4.20/share and 7.1M pre-funded warrants at $4.199/warrant for gross proceeds of $130M.
Underwriters granted 30-day option to purchase up to an additional 4.6M shares.
Proceeds to fund clinical development and regulatory approval of MOLBREEVI, plus commercialization and launch prep in US and EU.
Offering expected to close October 31, 2025, subject to customary conditions.
Jefferies, Piper Sandler, and Guggenheim Securities are joint book-running managers.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.